View Future GrowthInspireMD 過去の業績過去 基準チェック /06InspireMDの収益は年間平均-29.1%の割合で減少していますが、 Medical Equipment業界の収益は年間 増加しています。収益は年間15.3% 19.8%割合で 増加しています。主要情報-29.14%収益成長率33.79%EPS成長率Medical Equipment 業界の成長8.90%収益成長率19.78%株主資本利益率-117.64%ネット・マージン-472.98%前回の決算情報31 Mar 2026最近の業績更新Reported Earnings • May 06First quarter 2026 earnings released: US$0.16 loss per share (vs US$0.22 loss in 1Q 2025)First quarter 2026 results: US$0.16 loss per share. Revenue: US$3.40m (up 122% from 1Q 2025). Net loss: US$13.7m (loss widened 23% from 1Q 2025). Revenue is forecast to grow 46% p.a. on average during the next 2 years, compared to a 8.0% growth forecast for the Medical Equipment industry in the US.お知らせ • Apr 28InspireMD, Inc. to Report Q1, 2026 Results on May 04, 2026InspireMD, Inc. announced that they will report Q1, 2026 results on May 04, 2026Reported Earnings • Mar 18Full year 2025 earnings released: US$0.76 loss per share (vs US$0.76 loss in FY 2024)Full year 2025 results: US$0.76 loss per share. Revenue: US$8.98m (up 28% from FY 2024). Net loss: US$48.8m (loss widened 52% from FY 2024). Revenue is forecast to grow 56% p.a. on average during the next 2 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US.お知らせ • Mar 09InspireMD, Inc. to Report Q4, 2025 Results on Mar 18, 2026InspireMD, Inc. announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Mar 18, 2026Reported Earnings • Nov 04Third quarter 2025 earnings released: US$0.17 loss per share (vs US$0.16 loss in 3Q 2024)Third quarter 2025 results: US$0.17 loss per share (further deteriorated from US$0.16 loss in 3Q 2024). Revenue: US$2.52m (up 39% from 3Q 2024). Net loss: US$12.7m (loss widened 61% from 3Q 2024). Revenue is forecast to grow 69% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth.お知らせ • Oct 22InspireMD, Inc. to Report Q3, 2025 Results on Nov 04, 2025InspireMD, Inc. announced that they will report Q3, 2025 results on Nov 04, 2025すべての更新を表示Recent updatesお知らせ • Jul 03InspireMD, Inc. Announces Resignation of Raymond W. Cohen from Board and Committees, Effective July 1, 2026InspireMD, Inc. announced that Mr. Raymond W. Cohen, a Class III member of the board of directors, a member of the Audit Committee of the Board and a member of the Compensation Committee of the Board, tendered his resignation from the Board, effective July 1, 2026. Mr. Cohen's resignation from the Board was for personal considerations and not due to any disagreement with the Company, the Board or the management of the Company on any matter relating to the Company's operations, policies, practices or otherwise. The Nominating and Corporate Governance Committee of the Board intends to identify and evaluate suitable candidates to fill the vacancy created by Mr. Cohen's resignation.お知らせ • Jun 29+ 1 more updateInspireMD, Inc.(NasdaqCM:NSPR) dropped from Russell 3000E Growth BenchmarkInspireMD, Inc.(NasdaqCM:NSPR) dropped from Russell 3000E Growth Benchmarkお知らせ • Jun 22+ 5 more updatesInspireMD, Inc. Announces Recalling Action for CGuard Prime Carotid Stent System 135 cm, 9 mx40mmInspireMD, Inc. had recalled CGuard Prime Carotid Stent System, 135cm, 9mx40mm Model/Catalog Number: CND0940. Reason for Recall: Stent delivery system may encounter complications during deployment which may result in high resistance or inability to deploy the stent. Product Quantity: 291 units. Recall Number: Z-2328-2026. Code Information: UDI: 07290120281745; all lots/serial numbers manufactured between February 3, 2025 and February 23, 2026. Classification: Class II. Event Details Event ID: 98922. Voluntary /Mandated: Voluntary: Firm initiated. Product Type: Devices. Initial Firm Notification of Consignee or Public: E-Mail. Status: Ongoing. Distribution Pattern: US Nationwide distribution in the states of AR, AZ, CA, DC, FL, GA, HI, IL, IN, KS, MA, MD, MI, MO, NC, NJ, NV, NY, OH, OR, RI, SD, TN, TX, VA, WA, WI, WV. Recalling Firm: INSPIREMD Inc6303 Waterford District Dr Ste 215Miami, FL 33126-6004United States. Recall Initiation Date: May 1, 2026. Center Classification Date: June 5, 2026.お知らせ • Jun 09Inspiremd Enrolls First Patient in Cguardians Iii Pivotal Study of Switchguard Neuro Protection System for Use in Tcar ProceduresInspireMD, Inc. announced that the first patient has been enrolled in the CGUARDIANS III pivotal study of its SwitchGuard neuro protection system for use with its CGuard Prime 80 cm stent platform, in transcarotid artery revascularization procedures. The patient was enrolled at Good Samaritan Hospital, part of the TriHealth System in Cincinnati, Ohio. CGUARDIANS III is a prospective, multi-center, single-arm, pivotal study that will enroll approximately 103 subjects. The objective of the study is to evaluate the safety and efficacy of the SwitchGuard NPS in providing cerebral embolic protection during TCAR procedures using the CGuard Prime 80 cm stent system for the treatment of carotid artery stenosis in patients at high risk for complications from carotid endarterectomy.Recent Insider Transactions • May 11Insider recently bought US$106k worth of stockOn the 7th of May, Gary Roubin bought around 90k shares on-market at roughly US$1.18 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$186k more in shares than they have sold in the last 12 months.Reported Earnings • May 06First quarter 2026 earnings released: US$0.16 loss per share (vs US$0.22 loss in 1Q 2025)First quarter 2026 results: US$0.16 loss per share. Revenue: US$3.40m (up 122% from 1Q 2025). Net loss: US$13.7m (loss widened 23% from 1Q 2025). Revenue is forecast to grow 46% p.a. on average during the next 2 years, compared to a 8.0% growth forecast for the Medical Equipment industry in the US.お知らせ • Apr 28InspireMD, Inc. to Report Q1, 2026 Results on May 04, 2026InspireMD, Inc. announced that they will report Q1, 2026 results on May 04, 2026お知らせ • Apr 13InspireMD, Inc., Annual General Meeting, Jun 03, 2026InspireMD, Inc., Annual General Meeting, Jun 03, 2026. Location: 4 menorat hamaor st., tel-aviv., Israelお知らせ • Apr 04InspireMD, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.InspireMD, Inc. has filed a Follow-on Equity Offering in the amount of $75 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market OfferingReported Earnings • Mar 18Full year 2025 earnings released: US$0.76 loss per share (vs US$0.76 loss in FY 2024)Full year 2025 results: US$0.76 loss per share. Revenue: US$8.98m (up 28% from FY 2024). Net loss: US$48.8m (loss widened 52% from FY 2024). Revenue is forecast to grow 56% p.a. on average during the next 2 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US.お知らせ • Mar 18InspireMD, Inc. Provides Earnings Guidance for the Full Year 2026InspireMD, Inc. provided earnings guidance for the full year 2026. For the year, management currently expects revenue for the full year 2026 to be in the range of $13 million to $15 million, reflecting expected revenue growth of approximately 45% to 65% over 2025.お知らせ • Mar 09InspireMD, Inc. to Report Q4, 2025 Results on Mar 18, 2026InspireMD, Inc. announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Mar 18, 2026New Risk • Feb 03New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: US$99k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 28% per year over the past 5 years. Shareholders have been substantially diluted in the past year (62% increase in shares outstanding). Minor Risks Significant insider selling over the past 3 months (US$99k sold). Market cap is less than US$100m (US$69.1m market cap).Price Target Changed • Feb 02Price target increased by 15% to US$5.00Up from US$4.35, the current price target is an average from 3 analysts. New target price is 207% above last closing price of US$1.63. Stock is down 35% over the past year. The company posted a net loss per share of US$0.76 last year.分析記事 • Dec 24Is InspireMD (NASDAQ:NSPR) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...お知らせ • Dec 20InspireMD, Inc. Announces Resignation of Kathryn Arnold from Board of Directors and Board Committees, Effective December 31, 2025InspireMD, Inc. announced that Kathryn Arnold, a Class III member of the board of directors, a member of the compensation committee of the Board, the nominating and corporate governance committee of the Board, and the research and development committee of the Board, tendered her resignation from the Board, effective December 31, 2025. Ms. Arnold's resignation from the Board was not due to any disagreement with the Company, the Board or the management of the Company on any matter relating to the Company's operations, policies, practices or otherwise.お知らせ • Nov 05Inspiremd, Inc. Provides Revenue Guidance for the Fourth Quarter of 2025InspireMD, Inc. provided revenue guidance for the fourth quarter of 2025. For the fourth quarter, the company expects sequential growth in U.S. sales and steady demand trends internationally, resulting in revenue of approximately $2.5 million to $3.0 million in the fourth quarter.Reported Earnings • Nov 04Third quarter 2025 earnings released: US$0.17 loss per share (vs US$0.16 loss in 3Q 2024)Third quarter 2025 results: US$0.17 loss per share (further deteriorated from US$0.16 loss in 3Q 2024). Revenue: US$2.52m (up 39% from 3Q 2024). Net loss: US$12.7m (loss widened 61% from 3Q 2024). Revenue is forecast to grow 69% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth.お知らせ • Nov 04InspireMD, Inc. Appoints Peter A. Soukas, M.D., as Chief Medical OfficerInspireMD, Inc. announced the appointment of Peter A. Soukas, M.D., as Chief Medical Officer to advance its mission to deliver best-in-class tools for carotid intervention. Dr. Soukas brings significant experience and credentials in the field of vascular intervention to InspireMD. He serves as the Director of Vascular Medicine and the Peripheral Vascular Interventional Laboratory at The Miriam Hospital and is an Associate Professor of Medicine at The Warren Alpert Medical School of Brown University, where he also directs the Vascular and Endovascular Medicine Fellowship Program, which he founded. He is a Fellow of the American College of Cardiology, the Society of Vascular Medicine, the Society of Coronary Angiography and Interventions, and the American College of Physicians. In addition to his role at InspireMD, Dr. Soukas will be maintaining his clinical practice. Dr. Soukas’ clinical expertise and leadership in the interventional community speaks volumes for his passion and commitment to improving patient outcomes and advancing technology and innovation. He has served as the site principal investigator on more than 24 trials in carotid stenting, the site principal investigator on more than 150 endovascular trials, is a highly sought-after speaker having delivered over 300 invited lectures, and is a prolific researcher, publishing dozens of peer-reviewed papers with deep relationships among other key opinion leaders who shape the field. He is board certified in cardiovascular disease, interventional cardiology, vascular medicine, and endovascular medicine, and is certified in noninvasive vascular lab interpretation.お知らせ • Oct 22InspireMD, Inc. to Report Q3, 2025 Results on Nov 04, 2025InspireMD, Inc. announced that they will report Q3, 2025 results on Nov 04, 2025お知らせ • Sep 18InspireMD, Inc. Announces Resignation of Thomas J. Kester, A Class III Member of the Board of Directors, Member of the Compensation Committee, and the Chairman of the Audit Committee of the Board, Effective September 16, 2025On September 13, 2025, Mr. Thomas J. Kester, a Class III member of the board of directors of InspireMD, Inc., a member of the compensation committee of the Board (the “Compensation Committee”), and the chairman of the audit committee of the Board, tendered his resignation from the Board, effective September 16, 2025. Mr. Kester’s resignation from the Board was not due to any disagreement with the Company, the Board or the management of the Company on any matter relating to the Company’s operations, policies, practices or otherwise.お知らせ • Sep 17Inspiremd, Inc. Announces Appointment of Dan Dearen to Board of Directors, Chairman of the Audit Committee and A Member of the Compensation Committee, Effective September 16, 2025On September 16, 2025, InspireMD, Inc. announced the appointment of Dan Dearen to its Board of Directors. Mr. Dearen brings nearly 40 years of leadership experience in the medical device and life sciences sectors, with a proven track record of guiding MedTech companies through critical financial milestones and delivering shareholder value through execution. Mr. Dearen previously served as President, co-Founder, and Chief Financial Officer of Axonics, Inc., During his tenure, Axonics went public and became one of the fastest-growing companies in the medical device sector, helping over 300,000 patients find relief from bladder and bowel dysfunction. Axonics, Inc. was acquired by Boston Scientific in November 2024 for $3.7 billion. Until July 2024, Mr. Dearen also served as Chair of the Audit Committee and a Board member at Endotronix, a medical device company leveraging pulmonary artery (PA) pressure and vital sign data to improve care for patients with heart failure. He currently holds the same roles at JenaValve Technology, a developer of innovative transcatheter heart valve (THV) solutions, and BetaBionics, the creator of the iLet Bionic Pancreas, an autonomous insulin delivery system that determines every insulin dose for patients with diabetes. Prior to co-founding Axonics, Mr. Dearen held the role of Chief Operating and Financial Officer at Vessix Vascular, a medical device company focused on hypertension therapies, which Boston Scientific acquired in 2012 for $425 million. Mr. Dearen received his B.B.A. in Accounting and Business from Southern Methodist University and his M.B.A. from Boston College. Mr. Dearen’s appointment to the Board of Directors follows the appointment of Mr. Ray Cohen, announced in July 2025. In connection with his appointment, Mr. Dearen was also appointed as the chairman of the Audit Committee and a member of the Compensation Committee.お知らせ • Sep 09InspireMD, Inc. Appoints Raymond W. Cohen to Serve as A Member of the Audit Committee and the Compensation Committee of the Board, Effective September 7, 2025On September 7, 2025, the Board of InspireMD, Inc. appointed Mr. Raymond W. Cohen to serve as a member of the Audit Committee and the Compensation Committee of the Board.New Risk • Aug 06New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 62% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 26% per year over the past 5 years. Shareholders have been substantially diluted in the past year (62% increase in shares outstanding).Reported Earnings • Aug 05Second quarter 2025 earnings released: US$0.26 loss per share (vs US$0.22 loss in 2Q 2024)Second quarter 2025 results: US$0.26 loss per share (further deteriorated from US$0.22 loss in 2Q 2024). Revenue: US$1.78m (up 2.2% from 2Q 2024). Net loss: US$13.2m (loss widened 66% from 2Q 2024). Revenue is forecast to grow 67% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.お知らせ • Jul 31Inspiremd Announces Appointment of Raymond W. Cohen to Its Board of DirectorsInspireMD, Inc. announced the appointment of Raymond W. Cohen to its Board of Directors. Mr. Cohen has over 40 years of leadership experience in medical technology with a successful track record of scaling commercial operations and creating shareholder value through market leadership and successful exit transactions. Mr. Cohen was the CEO and co-founder of Axonics, Inc., which he took public in late 2018 and led through its $3.7 billion acquisition by Boston Scientific in November 2024. Axonics earned recognition as the number one fastest-growing company in the Americas by Deloitte and the Financial Times in 2021. Until May of 2025, Mr. Cohen served as Chairman of SoniVie Ltd., a clinical stage company focused on a device treatment for hypertension until it was acquired by Boston Scientific for $600 million. Cohen also serves as an independent director for Kestra Medical (Nasdaq: KMTS) and PE-backed Spectrum Vascular Inc., as well as Chairman of privately held Nalu Medical and Vice Chairman of privately held Tulavi, Inc. Previously, Cohen was CEO of Vessix Vascular, Inc., and publicly traded Cardiac Science Inc., a pioneer in automated external defibrillators which was later acquired by Zoll Medical. Mr. Cohen’s work has earned him numerous honors, including the MedTech MVP Award, EY Entrepreneur of the Year, and a Lifetime Achievement Award from SoCalBio.お知らせ • Jul 22InspireMD, Inc. to Report Q2, 2025 Results on Aug 05, 2025InspireMD, Inc. announced that they will report Q2, 2025 results on Aug 05, 2025お知らせ • Jun 25InspireMD, Inc. Announces FDA Approval for CGuard®? Prime Carotid Stent System for the Prevention of StrokeInspireMD, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted premarket application (PMA) approval of the CGuard Prime Carotid Stent System in the United States. The PMA approval is backed by best-in-class evidence from the Company's C-GUARDIANS pivotal trial, first presented at the Leipzig Interventional Course (LINC) in May 2024. CGuard Prime demonstrated the lowest 30-day (0.95%) and 1-year (1.93%) primary endpoint major adverse event rates of any pivotal study of carotid intervention. The Company's announcement of FDA approval of the CGuard Prime carotid Stent System triggers the second of four milestone-driven warrant tranches pursuant to the private placement financing of up to $113.6 million announced in May 2023. Proceeds, if any, will be used to support the imminent commercial launch of the CGuard Prime CarOTid Stent System in theUnited States, initiating new regulatory pathways for advanced applications of CGuard stent platform, and developing new products, while at the same time continuing to develop business outside of the United States.お知らせ • Jun 04InspireMD, Inc. Appoints Michael Lawless as Chief Financial Officer, Effective on or Prior to June 30, 2025InspireMD, Inc. announced the appointment of Michael Lawless, an industry veteran, as Chief Financial Officer, effective on or prior to June 30, 2025 (the “Effective Date”). On the Effective Date, Mr. Lawless will succeed Craig Shore, who has served as Chief Financial Officer of InspireMD for nearly 15 years.Mr. Lawless is an experienced public company CFO with decades of financial leadership throughout the healthcare space. For the past three years, he has served as CFO of Lifeward (formerly ReWalk Robotics). Previously, he served as the CFO of the $200 million Life Sciences unit of Brooks Automation. Mr. Lawless also served in several other senior corporate finance roles.Reported Earnings • May 10First quarter 2025 earnings released: US$0.22 loss per share (vs US$0.20 loss in 1Q 2024)First quarter 2025 results: US$0.22 loss per share (further deteriorated from US$0.20 loss in 1Q 2024). Revenue: US$1.53m (up 1.2% from 1Q 2024). Net loss: US$11.2m (loss widened 59% from 1Q 2024). Revenue is forecast to grow 65% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.New Risk • Apr 25New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 31% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 23% per year over the past 5 years. Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Minor Risk Market cap is less than US$100m (US$79.7m market cap).お知らせ • Apr 25InspireMD, Inc. to Report Q1, 2025 Results on May 09, 2025InspireMD, Inc. announced that they will report Q1, 2025 results on May 09, 2025お知らせ • Apr 16InspireMD, Inc., Annual General Meeting, Jun 03, 2025InspireMD, Inc., Annual General Meeting, Jun 03, 2025. Location: te offices of inspiremd , 4 menorat hamaor st., tel-aviv, israel United Statesお知らせ • Apr 02InspireMD, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.InspireMD, Inc. has filed a Follow-on Equity Offering in the amount of $75 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market OfferingNew Risk • Mar 13New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 27% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 23% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (27% increase in shares outstanding). Market cap is less than US$100m (US$83.4m market cap).Reported Earnings • Mar 12Full year 2024 earnings released: US$0.76 loss per share (vs US$0.82 loss in FY 2023)Full year 2024 results: US$0.76 loss per share. Revenue: US$7.01m (up 13% from FY 2023). Net loss: US$32.0m (loss widened 61% from FY 2023). Revenue is forecast to grow 57% p.a. on average during the next 3 years, compared to a 7.6% growth forecast for the Medical Equipment industry in the US.お知らせ • Feb 26InspireMD, Inc. to Report Q4, 2024 Results on Mar 12, 2025InspireMD, Inc. announced that they will report Q4, 2024 results on Mar 12, 2025お知らせ • Dec 12Craig Shore Decides to Retire as Chief Financial Officer of InspireMD, IncInspireMD, Inc. announced that Craig Shore, Chief Financial Officer, has decided to retire from the Company after a successor CFO is identified and appointed. Mr. Shore will remain as CFO until his successor is appointed and will assist in a smooth and orderly transition.Price Target Changed • Dec 11Price target increased by 9.2% to US$4.75Up from US$4.35, the current price target is an average from 2 analysts. New target price is 50% above last closing price of US$3.17. Stock is up 37% over the past year. The company posted a net loss per share of US$0.82 last year.お知らせ • Dec 10Inspiremd Announces First Patient Enrolled in the Cguardians Ii Pivotal Study of the Cguard Prime Carotid Stent System in Transcarotid Artery Revascularization ProceduresInspireMD, Inc. announced that the first patient has been enrolled in the company’s CGUARDIANS II clinical trial evaluating its CGuard Prime Carotid Stent System in patients undergoing carotid artery stenting via the Transcarotid Artery Revascularization (TCAR) approach. The patient was enrolled by Dr. Patrick Muck at Good Samaritan Hospital, part of the TriHealth System in Cincinnati, Ohio. Dr. Muck serves as both the site principal investigator as well as a co-lead investigator of the CGUARDIANS II study. CGUARDIANS II is a prospective, multi-center, single arm pivotal study that aims to enroll a minimum of 50 evaluable patients. The objective of this study is to evaluate acute device success and technical success of the CGuard Prime when used in conjunction with an FDA-cleared TCAR neuro-protection system in patients at high risk for adverse events from carotid endarterectomy.お知らせ • Nov 26InspireMD, Inc. Appoints Scott R. Ward to Its Board of DirectorsInspireMD, Inc. announced the appointment of accomplished medical technology executive Scott R. Ward to its Board of Directors. Mr. Ward most recently served as Chief Executive Officer and President of Cardiovascular Systems, Inc. prior to its acquisition by Abbott (NYSE: ABT) in April 2023. Mr. Ward has over 40 years of experience in the healthcare industry, including nearly 30 years at Medtronic, Inc. where he served in various leadership roles including as Senior Vice President and President of the CardioVascular, Neurological and Diabetes businesses. Mr. Ward is the Founder of Raymond Holdings, a firm with activities in venture capital, strategy and transactional advisory services for medical technology and life science companies. He earned his Bachelor of Science in Genetics and Cell Biology, his Master of Science in Toxicology, and his Master of Business Administration, all from the University of Minnesota.Reported Earnings • Nov 13Third quarter 2024 earnings released: US$0.16 loss per share (vs US$0.15 loss in 3Q 2023)Third quarter 2024 results: US$0.16 loss per share (further deteriorated from US$0.15 loss in 3Q 2023). Revenue: US$1.81m (up 16% from 3Q 2023). Net loss: US$7.89m (loss widened 52% from 3Q 2023). Revenue is forecast to grow 63% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.お知らせ • Nov 04InspireMD, Inc. to Report Q3, 2024 Results on Nov 12, 2024InspireMD, Inc. announced that they will report Q3, 2024 results Pre-Market on Nov 12, 2024お知らせ • Oct 07InspireMD, Inc. Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent SystemInspireMD, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational Device Exemption (IDE) Application to initiate the CGUARDIANS II pivotal study of its CGuard Prime 80cm Carotid Stent System during transcarotid revascularization (TCAR) procedures. In February 2024, InspireMD announced that Patrick Geraghty, M.D., professor of surgery and radiology, section of vascular surgery at Washington University School of Medicine in St. Louis, MO, and Patrick Muck, M.D., program director and chief of vascular surgery at Good Samaritan Hospital in Cincinnati, OH, have agreed to act as lead investigators for the trial.お知らせ • Sep 16InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent SystemInspireMD, Inc. announced that it has submitted a Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) seeking marketing approval for the CGuard Prime carotid stent system in the U.S. The PMA application is based on the overwhelmingly positive one-year data from the Company's C-GUARDIANS pivotal clinical trial that were presented at the Leipzig Interventional Course (LINC) 2024 in May. The C-GUARDIANS clinical trial evaluated the safety and efficacy of CGuard for the treatment of carotid artery stenosis. The study enrolled 316 patients across 24 trial sites in the U.S. and Europe. The C-GUARDIANS results showed a primary endpoint1 major adverse event rate of 1.95% through twelve months post-procedure, the lowest such event rate reported for any carotid stent or embolic protection device pivotal trial to date.Reported Earnings • Aug 06Second quarter 2024 earnings released: US$0.22 loss per share (vs US$0.24 loss in 2Q 2023)Second quarter 2024 results: US$0.22 loss per share. Revenue: US$1.74m (up 5.5% from 2Q 2023). Net loss: US$7.91m (loss widened 56% from 2Q 2023). Revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US.New Risk • Jul 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 20% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (US$82.9m market cap).お知らせ • Jul 30InspireMD, Inc. to Report Q2, 2024 Results on Aug 06, 2024InspireMD, Inc. announced that they will report Q2, 2024 results on Aug 06, 2024Recent Insider Transactions Derivative • Jun 28Independent Director exercised options to buy US$153k worth of stock.On the 24th of June, Michael Berman exercised options to buy 61k shares at a strike price of around US$1.38, costing a total of US$85k. This transaction amounted to 17% of their direct individual holding at the time of the trade. Since September 2023, Michael's direct individual holding has decreased from 318.62k shares to 127.88k. Company insiders have collectively bought US$296k more than they sold, via options and on-market transactions, in the last 12 months.Reported Earnings • May 15First quarter 2024 earnings released: US$0.20 loss per share (vs US$0.53 loss in 1Q 2023)First quarter 2024 results: US$0.20 loss per share. Revenue: US$1.51m (up 22% from 1Q 2023). Net loss: US$7.03m (loss widened 65% from 1Q 2023). Revenue is forecast to grow 54% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US.お知らせ • May 09InspireMD, Inc. to Report Q1, 2024 Results on May 14, 2024InspireMD, Inc. announced that they will report Q1, 2024 results Pre-Market on May 14, 2024Board Change • May 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 2 highly experienced directors. Chair of Scientific Advisory Board Ken Rosenfield was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Apr 20InspireMD, Inc., Annual General Meeting, Jun 10, 2024InspireMD, Inc., Annual General Meeting, Jun 10, 2024, at 10:00 US Eastern Standard Time. Location: 4 Menorat Hamaor St. Tel-Aviv Israel Agenda: To consider the election of two Class 1 directors to serve on board of directors for a term of three years or until his or her successor is elected and qualified, for which Paul Stuka and Gary Roubin are the nominees; to approve the Company's executive compensation; to approve the frequency of future advisory votes on the Company's executive compensation; to consider the ratification of the appointment of Kesselman & Kesselman, Certified Public Accountants, a member of PricewaterhouseCoopers International Limited, as independent registered public accounting firm for the year ending December 31, 2024; and to consider such other business as may properly come before the Annual Meeting.Major Estimate Revision • Mar 12Consensus revenue estimates decrease by 12%, EPS upgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from US$7.97m to US$7.05m. EPS estimate increased from -US$0.78 to -US$0.76 per share. Medical Equipment industry in the US expected to see average net income growth of 16% next year. Consensus price target of US$4.85 unchanged from last update. Share price fell 6.5% to US$2.46 over the past week.Reported Earnings • Mar 06Full year 2023 earnings: EPS and revenues exceed analyst expectationsFull year 2023 results: US$0.82 loss per share. Revenue: US$6.21m (up 20% from FY 2022). Net loss: US$19.9m (loss widened 7.7% from FY 2022). Revenue exceeded analyst estimates by 1.8%. Earnings per share (EPS) also surpassed analyst estimates by 5.7%. Revenue is forecast to grow 47% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US.お知らせ • Feb 29InspireMD, Inc. to Report Q4, 2023 Results on Mar 06, 2024InspireMD, Inc. announced that they will report Q4, 2023 results Pre-Market on Mar 06, 2024分析記事 • Jan 11Here's Why We're Not Too Worried About InspireMD's (NASDAQ:NSPR) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. By way of example, InspireMD...Recent Insider Transactions • Dec 05Insider recently bought US$127k worth of stockOn the 30th of November, Gary Roubin bought around 50k shares on-market at roughly US$2.53 per share. This transaction amounted to 13% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Major Estimate Revision • Nov 13Consensus EPS estimates fall by 13%The consensus outlook for fiscal year 2023 has been updated. 2023 expected loss increased from -US$0.77 to -US$0.87 per share. Revenue forecast unchanged at US$6.10m. Medical Equipment industry in the US expected to see average net income growth of 25% next year. Consensus price target of US$4.85 unchanged from last update. Share price fell 6.0% to US$3.14 over the past week.Price Target Changed • Nov 02Price target increased by 18% to US$4.85Up from US$4.13, the current price target is an average from 2 analysts. New target price is 45% above last closing price of US$3.34. Stock is up 201% over the past year. The company is forecast to post a net loss per share of US$0.77 next year compared to a net loss per share of US$2.35 last year.お知らせ • Nov 02Inspiremd, Inc. Presents Positive 30-Day Follow-Up Results from the C-Guard®? U.S. Investigational Device Exemption (Ide) Clinical TrialInspireMD, Inc. presented 30-day results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) clinical trial at the Vascular InterVentional Advances (VIVA) meeting, which is being held October 30 through November 2 in Las Vegas, NV. The presentation, which was accepted as a late-breaking abstract, was delivered by Dr. Chris Metzger, System Vascular Chief at OhioHealth in Columbus, OH and principal investigator of the C-GUARDIans trial. The company believe the neuroprotective qualities of C-Guard set it apart from competing stents on the market and should help accelerate the ongoing shift in carotid revascularizations from 'surgery first' to an endovascular 'stent first' approach. InspireMD anticipates reporting primary endpoint results from C-GUARDIANS in the second half of 2024 that may support a Premarket Approval (PMA) application.お知らせ • Oct 31InspireMD, Inc. to Report Q3, 2023 Results on Nov 06, 2023InspireMD, Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 06, 2023お知らせ • Oct 05InspireMD, Inc. Announces Management AppointmentsInspireMD, Inc. announced senior leadership additions and changes intended to support the company’s commercial growth initiatives, including potential approval of the CGuard Prime stent platform in the U.S., development of new stent delivery systems, and growth in existing approved territories outside of the U.S. The company announced that it has hired Patrick Verta, MD, as Executive Vice President of Clinical and Medical Affairs. In addition, Shane Gleason, who previously served as InspireMD’s General Manager of North America and VP of Global Marketing, has been promoted to Chief Commercial Officer. Dr. Patrick Verta joins InspireMD from Canary Medical, a developer of implantable remote patient monitoring sensor technology and complementary data and analytics, where he served as Chief Medical Officer. Prior to that, he was Founder and Chief Executive Officer of Axelmed LLC, a consultancy focused on strategy and clinical, scientific, medical, and regulatory affairs for medical device companies. Before Axelmed, he spent the prior five years in various roles at Edwards Lifesciences, most recently as VP of Global Medical Affairs, Clinical Science and Biometrics in the Transcatheter Mitral and Tricuspid Therapies (TMTT) division. Earlier in his career, he held senior leadership positions at Sunshine Heart, Neomend, Abbott Vascular (part of Abbott) and Guidant (acquired by Abbott), among others. Dr. Verta received his Doctor of Medicine (M.D.) from Faculté de Médecine in Paris.Major Estimate Revision • Aug 14Consensus EPS estimates upgraded to US$0.77 lossThe consensus outlook for fiscal year 2023 has been updated. 2023 losses forecast to reduce from -US$1.37 to -US$0.77 per share. Revenue forecast steady at US$6.07m. Medical Equipment industry in the US expected to see average net income growth of 23% next year. Consensus price target up from US$4.13 to US$4.35. Share price rose 3.5% to US$3.21 over the past week.Price Target Changed • Aug 09Price target increased by 12% to US$4.35Up from US$3.88, the current price target is an average from 2 analysts. New target price is 40% above last closing price of US$3.10. Stock is up 61% over the past year. The company is forecast to post a net loss per share of US$0.77 next year compared to a net loss per share of US$2.35 last year.Reported Earnings • Aug 08Second quarter 2023 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2023 results: US$0.24 loss per share. Revenue: US$1.65m (up 7.7% from 2Q 2022). Net loss: US$5.08m (loss widened 9.5% from 2Q 2022). Revenue exceeded analyst estimates by 6.7%. Earnings per share (EPS) also surpassed analyst estimates by 44%. Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US.お知らせ • Jul 29InspireMD, Inc., Annual General Meeting, Sep 13, 2023InspireMD, Inc., Annual General Meeting, Sep 13, 2023, at 10:00 US Eastern Standard Time. Location: 4 Menorat Hamaor St. Tel-Aviv Israel Agenda: T consider the election of three Class 3 directors to serve on board of directors for a term of three years or until his or her successor is elected and qualified, for which Marvin Slosman, Thomas J. Kester and Kathryn Arnold are the nominees; to approve the potential issuance of shares in the Private Placement Offering; to approve an amendment to Amended and Restated Certificate of Incorporation to limit the liability of certain officers of the Company as permitted by recent amendments to Delaware law; to consider the ratification of the appointment of Kesselman & Kesselman, Certified Public Accountants, a member of PricewaterhouseCoopers International Limited, as independent registered public accounting firm for the year ending December 31, 2023; and to consider such other business as may properly come before the Annual Meeting.お知らせ • Jul 26InspireMD, Inc. to Report Q2, 2023 Results on Aug 08, 2023InspireMD, Inc. announced that they will report Q2, 2023 results Pre-Market on Aug 08, 2023お知らせ • Jun 28InspireMD, Inc. Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption Clinical TrialInspireMD, Inc. announced that it completed enrollment of its ongoing C-Guardians U.S. Investigational Device Exemption (IDE) clinical trial, designed to support potential U.S. marketing approval of the CGuard Prime EPS stent system. The C-Guardians clinical trial is evaluating the safety and efficacy of the CGuard™ Carotid Stent System for the treatment of carotid artery stenosis. The study, which commenced enrollment in July 2021, enrolled 315 patients across 25 trial sites in the U.S. and Europe. The trial includes both symptomatic and asymptomatic patients undergoing carotid artery stenting (CAS). The primary endpoint includes the composite of the following: incidence of the following major adverse events: death (all- cause mortality), all stroke, and myocardial infarction (DSMI) through 30-days post-index procedure, based on the Clinical Events Committee (CEC) adjudication or ipsilateral stroke from 31-365-day follow-up, based on CEC adjudication. The performance goal will be considered to have been met if the upper bound of the two-sided 95% confidence interval calculated from the observed primary endpoint rate is <11.6% and the p-value is <0.025. The company anticipates results from the study in second half 2024.Major Estimate Revision • May 19Consensus estimates of losses per share improve by 46%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from US$5.70m to US$5.90m. EPS estimate increased from -US$2.56 per share to -US$1.37 per share. Medical Equipment industry in the US expected to see average net income growth of 18% next year. Consensus price target down from US$5.15 to US$4.75. Share price rose 23% to US$1.70 over the past week.お知らせ • May 17InspireMD, Inc. announced that it has received $42.169643 million in funding from Marshall Wace LLP, OrbiMed Advisors LLC, Nantahala Capital Management, LLC, Soleus Capital Management, L.P., Velan Inc. and other investorsOn May 16, 2023, InspireMD, Inc. closed the transaction.お知らせ • May 06InspireMD, Inc. to Report Q1, 2023 Results on May 15, 2023InspireMD, Inc. announced that they will report Q1, 2023 results on May 15, 2023Major Estimate Revision • Apr 02Consensus revenue estimates decrease by 37%, EPS upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from US$9.00m to US$5.70m. EPS estimate increased from -US$2.61 to -US$2.56 per share. Medical Equipment industry in the US expected to see average net income growth of 16% next year. Consensus price target down from US$5.60 to US$5.15. Share price rose 3.7% to US$1.13 over the past week.Price Target Changed • Nov 16Price target decreased to US$5.60Down from US$16.50, the current price target is provided by 1 analyst. New target price is 454% above last closing price of US$1.01. Stock is down 74% over the past year. The company is forecast to post a net loss per share of US$2.59 next year compared to a net loss per share of US$2.03 last year.Reported Earnings • Nov 10Third quarter 2022 earnings: EPS and revenues exceed analyst expectationsThird quarter 2022 results: US$0.58 loss per share (further deteriorated from US$0.53 loss in 3Q 2021). Revenue: US$1.43m (up 34% from 3Q 2021). Net loss: US$4.53m (loss widened 11% from 3Q 2021). Revenue exceeded analyst estimates by 2.2%. Earnings per share (EPS) also surpassed analyst estimates by 21%. Revenue is forecast to grow 48% p.a. on average during the next 2 years, compared to a 7.4% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 128% per year but the company’s share price has fallen by 60% per year, which means it is significantly lagging earnings.Recent Insider Transactions • Aug 23Insider recently bought US$68k worth of stockOn the 18th of August, Gary Roubin bought around 36k shares on-market at roughly US$1.91 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$311k more in shares than they have sold in the last 12 months.Reported Earnings • Aug 10Second quarter 2022 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2022 results: US$0.59 loss per share (down from US$0.46 loss in 2Q 2021). Revenue: US$1.53m (up 48% from 2Q 2021). Net loss: US$4.64m (loss widened 32% from 2Q 2021). Revenue exceeded analyst estimates by 28%. Earnings per share (EPS) also surpassed analyst estimates by 19%. Over the next year, revenue is forecast to grow 37%, compared to a 6.2% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 125% per year but the company’s share price has fallen by 60% per year, which means it is significantly lagging earnings.Reported Earnings • May 12First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2022 results: US$0.57 loss per share (down from US$0.53 loss in 1Q 2021). Revenue: US$1.18m (up 18% from 1Q 2021). Net loss: US$4.48m (loss widened 38% from 1Q 2021). Revenue missed analyst estimates by 15%. Earnings per share (EPS) exceeded analyst estimates by 29%. Over the next year, revenue is forecast to grow 50%, compared to a 8.8% growth forecast for the industry in the US.Price Target Changed • Apr 27Price target decreased to US$9.00Down from US$16.50, the current price target is provided by 1 analyst. New target price is 250% above last closing price of US$2.57. Stock is down 61% over the past year. The company is forecast to post a net loss per share of US$3.20 next year compared to a net loss per share of US$2.03 last year.Reported Earnings • Mar 10Full year 2021 earnings: EPS misses analyst expectationsFull year 2021 results: US$2.03 loss per share (up from US$6.97 loss in FY 2020). Revenue: US$4.50m (up 81% from FY 2020). Net loss: US$14.9m (loss widened 42% from FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 12%. Over the next year, revenue is forecast to grow 31%, compared to a 11% growth forecast for the industry in the US.分析記事 • Jan 27We Think InspireMD (NASDAQ:NSPR) Needs To Drive Business Growth CarefullyJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Recent Insider Transactions • Jan 01Insider recently bought US$50k worth of stockOn the 28th of December, Gary Roubin bought around 16k shares on-market at roughly US$3.08 per share. In the last 3 months, they made an even bigger purchase worth US$100k. Insiders have collectively bought US$244k more in shares than they have sold in the last 12 months.Recent Insider Transactions • Nov 19Insider recently bought US$100k worth of stockOn the 17th of November, Gary Roubin bought around 26k shares on-market at roughly US$3.86 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$193k more in shares than they have sold in the last 12 months.Reported Earnings • Nov 11Third quarter 2021 earnings released: US$0.53 loss per share (vs US$0.96 loss in 3Q 2020)The company reported a soft third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: US$1.07m (up 9.3% from 3Q 2020). Net loss: US$4.07m (loss widened 82% from 3Q 2020).分析記事 • Oct 05We're Keeping An Eye On InspireMD's (NASDAQ:NSPR) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Seeking Alpha • Sep 20InspireMD: Revolutionizing The Field Of Vascular StentingInspireMD develops and commercializes proprietary stent designs with a proprietary mesh. The Company seeks to change the SoC in the treatment of CAD and other invasive indications utilizing an integrated embolic protection stent platform. The Company’s commercialized products are CE mark approved but not approved for sale in the U.S. The Company has initiated a U.S. registrational IDE clinical trial for CGuard EPS in July 2021.Recent Insider Transactions • Aug 28Insider recently bought US$93k worth of stockOn the 25th of August, Gary Roubin bought around 22k shares on-market at roughly US$4.19 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Major Estimate Revision • Aug 17Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from US$4.90m to US$4.60m. 2021 losses expected to reduce from -US$547 to -US$2.62 per share. Medical Equipment industry in the US expected to see average net income growth of 20% next year. Consensus price target of US$16.50 unchanged from last update. Share price fell 7.1% to US$3.68 over the past week.Reported Earnings • Aug 12Second quarter 2021 earnings released: US$0.46 loss per share (vs US$2.93 loss in 2Q 2020)Second quarter 2021 results: Net loss: US$3.51m (loss widened 41% from 2Q 2020).Reported Earnings • May 12First quarter 2021 earnings released: US$0.53 loss per share (vs US$6.42 loss in 1Q 2020)First quarter 2021 results: Net loss: US$3.24m (loss widened 64% from 1Q 2020).Reported Earnings • Mar 10Full year 2020 earnings released: US$0.47 loss per share (vs US$4.80 loss in FY 2019)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: US$2.49m (down 33% from FY 2019). Net loss: US$10.5m (loss widened 5.0% from FY 2019). Over the last 3 years on average, earnings per share has increased by 165% per year but the company’s share price has fallen by 82% per year, which means it is significantly lagging earnings.Analyst Estimate Surprise Post Earnings • Mar 10Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 24%. Earnings per share (EPS) exceeded analyst estimates by 4.5%. Over the next year, revenue is forecast to grow 137%, compared to a 21% growth forecast for the Medical Equipment industry in the US.分析記事 • Feb 11Trade Alert: Gary Roubin At InspireMD, Inc. (NYSEMKT:NSPR), Has Just Spent US$150k Buying 52% More SharesInvestors who take an interest in InspireMD, Inc. ( NYSEMKT:NSPR ) should definitely note that insider Gary Roubin...収支内訳InspireMD の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史NasdaqCM:NSPR 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Mar 2611-51391631 Dec 259-49371530 Sep 258-46341530 Jun 257-41281631 Mar 257-36241531 Dec 247-32211430 Sep 247-28201230 Jun 247-26191031 Mar 246-2317931 Dec 236-2015830 Sep 235-1914830 Jun 235-1913831 Mar 235-1812831 Dec 225-1812830 Sep 226-1812730 Jun 225-1711731 Mar 225-1611631 Dec 214-1510530 Sep 213-1510430 Jun 213-139331 Mar 212-129331 Dec 202-118230 Sep 203-98230 Jun 203-98231 Mar 204-97231 Dec 194-108330 Sep 194-107330 Jun 193-107331 Mar 193-87231 Dec 184-87230 Sep 184-117130 Jun 184-117131 Mar 183-127131 Dec 173-138130 Sep 172-108130 Jun 172-107131 Mar 172-97131 Dec 162-86130 Sep 162-96230 Jun 162-117231 Mar 162-138331 Dec 152-1610430 Sep 153-18114質の高い収益: NSPRは現在利益が出ていません。利益率の向上: NSPRは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: NSPRは利益が出ておらず、過去 5 年間で損失は年間29.1%の割合で増加しています。成長の加速: NSPRの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: NSPRは利益が出ていないため、過去 1 年間の収益成長をMedical Equipment業界 ( 14.8% ) と比較することは困難です。株主資本利益率高いROE: NSPRは現在利益が出ていないため、自己資本利益率 ( -117.64% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YHealthcare 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/05 04:16終値2026/07/02 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋InspireMD, Inc. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8 アナリスト機関Raymond MyersBenchmark CompanyKeay NakaeChardan Capital Markets, LLCJose De Jesus HarescoCitizens JMP Securities, LLC5 その他のアナリストを表示
Reported Earnings • May 06First quarter 2026 earnings released: US$0.16 loss per share (vs US$0.22 loss in 1Q 2025)First quarter 2026 results: US$0.16 loss per share. Revenue: US$3.40m (up 122% from 1Q 2025). Net loss: US$13.7m (loss widened 23% from 1Q 2025). Revenue is forecast to grow 46% p.a. on average during the next 2 years, compared to a 8.0% growth forecast for the Medical Equipment industry in the US.
お知らせ • Apr 28InspireMD, Inc. to Report Q1, 2026 Results on May 04, 2026InspireMD, Inc. announced that they will report Q1, 2026 results on May 04, 2026
Reported Earnings • Mar 18Full year 2025 earnings released: US$0.76 loss per share (vs US$0.76 loss in FY 2024)Full year 2025 results: US$0.76 loss per share. Revenue: US$8.98m (up 28% from FY 2024). Net loss: US$48.8m (loss widened 52% from FY 2024). Revenue is forecast to grow 56% p.a. on average during the next 2 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US.
お知らせ • Mar 09InspireMD, Inc. to Report Q4, 2025 Results on Mar 18, 2026InspireMD, Inc. announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Mar 18, 2026
Reported Earnings • Nov 04Third quarter 2025 earnings released: US$0.17 loss per share (vs US$0.16 loss in 3Q 2024)Third quarter 2025 results: US$0.17 loss per share (further deteriorated from US$0.16 loss in 3Q 2024). Revenue: US$2.52m (up 39% from 3Q 2024). Net loss: US$12.7m (loss widened 61% from 3Q 2024). Revenue is forecast to grow 69% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth.
お知らせ • Oct 22InspireMD, Inc. to Report Q3, 2025 Results on Nov 04, 2025InspireMD, Inc. announced that they will report Q3, 2025 results on Nov 04, 2025
お知らせ • Jul 03InspireMD, Inc. Announces Resignation of Raymond W. Cohen from Board and Committees, Effective July 1, 2026InspireMD, Inc. announced that Mr. Raymond W. Cohen, a Class III member of the board of directors, a member of the Audit Committee of the Board and a member of the Compensation Committee of the Board, tendered his resignation from the Board, effective July 1, 2026. Mr. Cohen's resignation from the Board was for personal considerations and not due to any disagreement with the Company, the Board or the management of the Company on any matter relating to the Company's operations, policies, practices or otherwise. The Nominating and Corporate Governance Committee of the Board intends to identify and evaluate suitable candidates to fill the vacancy created by Mr. Cohen's resignation.
お知らせ • Jun 29+ 1 more updateInspireMD, Inc.(NasdaqCM:NSPR) dropped from Russell 3000E Growth BenchmarkInspireMD, Inc.(NasdaqCM:NSPR) dropped from Russell 3000E Growth Benchmark
お知らせ • Jun 22+ 5 more updatesInspireMD, Inc. Announces Recalling Action for CGuard Prime Carotid Stent System 135 cm, 9 mx40mmInspireMD, Inc. had recalled CGuard Prime Carotid Stent System, 135cm, 9mx40mm Model/Catalog Number: CND0940. Reason for Recall: Stent delivery system may encounter complications during deployment which may result in high resistance or inability to deploy the stent. Product Quantity: 291 units. Recall Number: Z-2328-2026. Code Information: UDI: 07290120281745; all lots/serial numbers manufactured between February 3, 2025 and February 23, 2026. Classification: Class II. Event Details Event ID: 98922. Voluntary /Mandated: Voluntary: Firm initiated. Product Type: Devices. Initial Firm Notification of Consignee or Public: E-Mail. Status: Ongoing. Distribution Pattern: US Nationwide distribution in the states of AR, AZ, CA, DC, FL, GA, HI, IL, IN, KS, MA, MD, MI, MO, NC, NJ, NV, NY, OH, OR, RI, SD, TN, TX, VA, WA, WI, WV. Recalling Firm: INSPIREMD Inc6303 Waterford District Dr Ste 215Miami, FL 33126-6004United States. Recall Initiation Date: May 1, 2026. Center Classification Date: June 5, 2026.
お知らせ • Jun 09Inspiremd Enrolls First Patient in Cguardians Iii Pivotal Study of Switchguard Neuro Protection System for Use in Tcar ProceduresInspireMD, Inc. announced that the first patient has been enrolled in the CGUARDIANS III pivotal study of its SwitchGuard neuro protection system for use with its CGuard Prime 80 cm stent platform, in transcarotid artery revascularization procedures. The patient was enrolled at Good Samaritan Hospital, part of the TriHealth System in Cincinnati, Ohio. CGUARDIANS III is a prospective, multi-center, single-arm, pivotal study that will enroll approximately 103 subjects. The objective of the study is to evaluate the safety and efficacy of the SwitchGuard NPS in providing cerebral embolic protection during TCAR procedures using the CGuard Prime 80 cm stent system for the treatment of carotid artery stenosis in patients at high risk for complications from carotid endarterectomy.
Recent Insider Transactions • May 11Insider recently bought US$106k worth of stockOn the 7th of May, Gary Roubin bought around 90k shares on-market at roughly US$1.18 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$186k more in shares than they have sold in the last 12 months.
Reported Earnings • May 06First quarter 2026 earnings released: US$0.16 loss per share (vs US$0.22 loss in 1Q 2025)First quarter 2026 results: US$0.16 loss per share. Revenue: US$3.40m (up 122% from 1Q 2025). Net loss: US$13.7m (loss widened 23% from 1Q 2025). Revenue is forecast to grow 46% p.a. on average during the next 2 years, compared to a 8.0% growth forecast for the Medical Equipment industry in the US.
お知らせ • Apr 28InspireMD, Inc. to Report Q1, 2026 Results on May 04, 2026InspireMD, Inc. announced that they will report Q1, 2026 results on May 04, 2026
お知らせ • Apr 13InspireMD, Inc., Annual General Meeting, Jun 03, 2026InspireMD, Inc., Annual General Meeting, Jun 03, 2026. Location: 4 menorat hamaor st., tel-aviv., Israel
お知らせ • Apr 04InspireMD, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.InspireMD, Inc. has filed a Follow-on Equity Offering in the amount of $75 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
Reported Earnings • Mar 18Full year 2025 earnings released: US$0.76 loss per share (vs US$0.76 loss in FY 2024)Full year 2025 results: US$0.76 loss per share. Revenue: US$8.98m (up 28% from FY 2024). Net loss: US$48.8m (loss widened 52% from FY 2024). Revenue is forecast to grow 56% p.a. on average during the next 2 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US.
お知らせ • Mar 18InspireMD, Inc. Provides Earnings Guidance for the Full Year 2026InspireMD, Inc. provided earnings guidance for the full year 2026. For the year, management currently expects revenue for the full year 2026 to be in the range of $13 million to $15 million, reflecting expected revenue growth of approximately 45% to 65% over 2025.
お知らせ • Mar 09InspireMD, Inc. to Report Q4, 2025 Results on Mar 18, 2026InspireMD, Inc. announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Mar 18, 2026
New Risk • Feb 03New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: US$99k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 28% per year over the past 5 years. Shareholders have been substantially diluted in the past year (62% increase in shares outstanding). Minor Risks Significant insider selling over the past 3 months (US$99k sold). Market cap is less than US$100m (US$69.1m market cap).
Price Target Changed • Feb 02Price target increased by 15% to US$5.00Up from US$4.35, the current price target is an average from 3 analysts. New target price is 207% above last closing price of US$1.63. Stock is down 35% over the past year. The company posted a net loss per share of US$0.76 last year.
分析記事 • Dec 24Is InspireMD (NASDAQ:NSPR) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
お知らせ • Dec 20InspireMD, Inc. Announces Resignation of Kathryn Arnold from Board of Directors and Board Committees, Effective December 31, 2025InspireMD, Inc. announced that Kathryn Arnold, a Class III member of the board of directors, a member of the compensation committee of the Board, the nominating and corporate governance committee of the Board, and the research and development committee of the Board, tendered her resignation from the Board, effective December 31, 2025. Ms. Arnold's resignation from the Board was not due to any disagreement with the Company, the Board or the management of the Company on any matter relating to the Company's operations, policies, practices or otherwise.
お知らせ • Nov 05Inspiremd, Inc. Provides Revenue Guidance for the Fourth Quarter of 2025InspireMD, Inc. provided revenue guidance for the fourth quarter of 2025. For the fourth quarter, the company expects sequential growth in U.S. sales and steady demand trends internationally, resulting in revenue of approximately $2.5 million to $3.0 million in the fourth quarter.
Reported Earnings • Nov 04Third quarter 2025 earnings released: US$0.17 loss per share (vs US$0.16 loss in 3Q 2024)Third quarter 2025 results: US$0.17 loss per share (further deteriorated from US$0.16 loss in 3Q 2024). Revenue: US$2.52m (up 39% from 3Q 2024). Net loss: US$12.7m (loss widened 61% from 3Q 2024). Revenue is forecast to grow 69% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth.
お知らせ • Nov 04InspireMD, Inc. Appoints Peter A. Soukas, M.D., as Chief Medical OfficerInspireMD, Inc. announced the appointment of Peter A. Soukas, M.D., as Chief Medical Officer to advance its mission to deliver best-in-class tools for carotid intervention. Dr. Soukas brings significant experience and credentials in the field of vascular intervention to InspireMD. He serves as the Director of Vascular Medicine and the Peripheral Vascular Interventional Laboratory at The Miriam Hospital and is an Associate Professor of Medicine at The Warren Alpert Medical School of Brown University, where he also directs the Vascular and Endovascular Medicine Fellowship Program, which he founded. He is a Fellow of the American College of Cardiology, the Society of Vascular Medicine, the Society of Coronary Angiography and Interventions, and the American College of Physicians. In addition to his role at InspireMD, Dr. Soukas will be maintaining his clinical practice. Dr. Soukas’ clinical expertise and leadership in the interventional community speaks volumes for his passion and commitment to improving patient outcomes and advancing technology and innovation. He has served as the site principal investigator on more than 24 trials in carotid stenting, the site principal investigator on more than 150 endovascular trials, is a highly sought-after speaker having delivered over 300 invited lectures, and is a prolific researcher, publishing dozens of peer-reviewed papers with deep relationships among other key opinion leaders who shape the field. He is board certified in cardiovascular disease, interventional cardiology, vascular medicine, and endovascular medicine, and is certified in noninvasive vascular lab interpretation.
お知らせ • Oct 22InspireMD, Inc. to Report Q3, 2025 Results on Nov 04, 2025InspireMD, Inc. announced that they will report Q3, 2025 results on Nov 04, 2025
お知らせ • Sep 18InspireMD, Inc. Announces Resignation of Thomas J. Kester, A Class III Member of the Board of Directors, Member of the Compensation Committee, and the Chairman of the Audit Committee of the Board, Effective September 16, 2025On September 13, 2025, Mr. Thomas J. Kester, a Class III member of the board of directors of InspireMD, Inc., a member of the compensation committee of the Board (the “Compensation Committee”), and the chairman of the audit committee of the Board, tendered his resignation from the Board, effective September 16, 2025. Mr. Kester’s resignation from the Board was not due to any disagreement with the Company, the Board or the management of the Company on any matter relating to the Company’s operations, policies, practices or otherwise.
お知らせ • Sep 17Inspiremd, Inc. Announces Appointment of Dan Dearen to Board of Directors, Chairman of the Audit Committee and A Member of the Compensation Committee, Effective September 16, 2025On September 16, 2025, InspireMD, Inc. announced the appointment of Dan Dearen to its Board of Directors. Mr. Dearen brings nearly 40 years of leadership experience in the medical device and life sciences sectors, with a proven track record of guiding MedTech companies through critical financial milestones and delivering shareholder value through execution. Mr. Dearen previously served as President, co-Founder, and Chief Financial Officer of Axonics, Inc., During his tenure, Axonics went public and became one of the fastest-growing companies in the medical device sector, helping over 300,000 patients find relief from bladder and bowel dysfunction. Axonics, Inc. was acquired by Boston Scientific in November 2024 for $3.7 billion. Until July 2024, Mr. Dearen also served as Chair of the Audit Committee and a Board member at Endotronix, a medical device company leveraging pulmonary artery (PA) pressure and vital sign data to improve care for patients with heart failure. He currently holds the same roles at JenaValve Technology, a developer of innovative transcatheter heart valve (THV) solutions, and BetaBionics, the creator of the iLet Bionic Pancreas, an autonomous insulin delivery system that determines every insulin dose for patients with diabetes. Prior to co-founding Axonics, Mr. Dearen held the role of Chief Operating and Financial Officer at Vessix Vascular, a medical device company focused on hypertension therapies, which Boston Scientific acquired in 2012 for $425 million. Mr. Dearen received his B.B.A. in Accounting and Business from Southern Methodist University and his M.B.A. from Boston College. Mr. Dearen’s appointment to the Board of Directors follows the appointment of Mr. Ray Cohen, announced in July 2025. In connection with his appointment, Mr. Dearen was also appointed as the chairman of the Audit Committee and a member of the Compensation Committee.
お知らせ • Sep 09InspireMD, Inc. Appoints Raymond W. Cohen to Serve as A Member of the Audit Committee and the Compensation Committee of the Board, Effective September 7, 2025On September 7, 2025, the Board of InspireMD, Inc. appointed Mr. Raymond W. Cohen to serve as a member of the Audit Committee and the Compensation Committee of the Board.
New Risk • Aug 06New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 62% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 26% per year over the past 5 years. Shareholders have been substantially diluted in the past year (62% increase in shares outstanding).
Reported Earnings • Aug 05Second quarter 2025 earnings released: US$0.26 loss per share (vs US$0.22 loss in 2Q 2024)Second quarter 2025 results: US$0.26 loss per share (further deteriorated from US$0.22 loss in 2Q 2024). Revenue: US$1.78m (up 2.2% from 2Q 2024). Net loss: US$13.2m (loss widened 66% from 2Q 2024). Revenue is forecast to grow 67% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
お知らせ • Jul 31Inspiremd Announces Appointment of Raymond W. Cohen to Its Board of DirectorsInspireMD, Inc. announced the appointment of Raymond W. Cohen to its Board of Directors. Mr. Cohen has over 40 years of leadership experience in medical technology with a successful track record of scaling commercial operations and creating shareholder value through market leadership and successful exit transactions. Mr. Cohen was the CEO and co-founder of Axonics, Inc., which he took public in late 2018 and led through its $3.7 billion acquisition by Boston Scientific in November 2024. Axonics earned recognition as the number one fastest-growing company in the Americas by Deloitte and the Financial Times in 2021. Until May of 2025, Mr. Cohen served as Chairman of SoniVie Ltd., a clinical stage company focused on a device treatment for hypertension until it was acquired by Boston Scientific for $600 million. Cohen also serves as an independent director for Kestra Medical (Nasdaq: KMTS) and PE-backed Spectrum Vascular Inc., as well as Chairman of privately held Nalu Medical and Vice Chairman of privately held Tulavi, Inc. Previously, Cohen was CEO of Vessix Vascular, Inc., and publicly traded Cardiac Science Inc., a pioneer in automated external defibrillators which was later acquired by Zoll Medical. Mr. Cohen’s work has earned him numerous honors, including the MedTech MVP Award, EY Entrepreneur of the Year, and a Lifetime Achievement Award from SoCalBio.
お知らせ • Jul 22InspireMD, Inc. to Report Q2, 2025 Results on Aug 05, 2025InspireMD, Inc. announced that they will report Q2, 2025 results on Aug 05, 2025
お知らせ • Jun 25InspireMD, Inc. Announces FDA Approval for CGuard®? Prime Carotid Stent System for the Prevention of StrokeInspireMD, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted premarket application (PMA) approval of the CGuard Prime Carotid Stent System in the United States. The PMA approval is backed by best-in-class evidence from the Company's C-GUARDIANS pivotal trial, first presented at the Leipzig Interventional Course (LINC) in May 2024. CGuard Prime demonstrated the lowest 30-day (0.95%) and 1-year (1.93%) primary endpoint major adverse event rates of any pivotal study of carotid intervention. The Company's announcement of FDA approval of the CGuard Prime carotid Stent System triggers the second of four milestone-driven warrant tranches pursuant to the private placement financing of up to $113.6 million announced in May 2023. Proceeds, if any, will be used to support the imminent commercial launch of the CGuard Prime CarOTid Stent System in theUnited States, initiating new regulatory pathways for advanced applications of CGuard stent platform, and developing new products, while at the same time continuing to develop business outside of the United States.
お知らせ • Jun 04InspireMD, Inc. Appoints Michael Lawless as Chief Financial Officer, Effective on or Prior to June 30, 2025InspireMD, Inc. announced the appointment of Michael Lawless, an industry veteran, as Chief Financial Officer, effective on or prior to June 30, 2025 (the “Effective Date”). On the Effective Date, Mr. Lawless will succeed Craig Shore, who has served as Chief Financial Officer of InspireMD for nearly 15 years.Mr. Lawless is an experienced public company CFO with decades of financial leadership throughout the healthcare space. For the past three years, he has served as CFO of Lifeward (formerly ReWalk Robotics). Previously, he served as the CFO of the $200 million Life Sciences unit of Brooks Automation. Mr. Lawless also served in several other senior corporate finance roles.
Reported Earnings • May 10First quarter 2025 earnings released: US$0.22 loss per share (vs US$0.20 loss in 1Q 2024)First quarter 2025 results: US$0.22 loss per share (further deteriorated from US$0.20 loss in 1Q 2024). Revenue: US$1.53m (up 1.2% from 1Q 2024). Net loss: US$11.2m (loss widened 59% from 1Q 2024). Revenue is forecast to grow 65% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
New Risk • Apr 25New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 31% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 23% per year over the past 5 years. Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Minor Risk Market cap is less than US$100m (US$79.7m market cap).
お知らせ • Apr 25InspireMD, Inc. to Report Q1, 2025 Results on May 09, 2025InspireMD, Inc. announced that they will report Q1, 2025 results on May 09, 2025
お知らせ • Apr 16InspireMD, Inc., Annual General Meeting, Jun 03, 2025InspireMD, Inc., Annual General Meeting, Jun 03, 2025. Location: te offices of inspiremd , 4 menorat hamaor st., tel-aviv, israel United States
お知らせ • Apr 02InspireMD, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.InspireMD, Inc. has filed a Follow-on Equity Offering in the amount of $75 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
New Risk • Mar 13New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 27% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 23% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (27% increase in shares outstanding). Market cap is less than US$100m (US$83.4m market cap).
Reported Earnings • Mar 12Full year 2024 earnings released: US$0.76 loss per share (vs US$0.82 loss in FY 2023)Full year 2024 results: US$0.76 loss per share. Revenue: US$7.01m (up 13% from FY 2023). Net loss: US$32.0m (loss widened 61% from FY 2023). Revenue is forecast to grow 57% p.a. on average during the next 3 years, compared to a 7.6% growth forecast for the Medical Equipment industry in the US.
お知らせ • Feb 26InspireMD, Inc. to Report Q4, 2024 Results on Mar 12, 2025InspireMD, Inc. announced that they will report Q4, 2024 results on Mar 12, 2025
お知らせ • Dec 12Craig Shore Decides to Retire as Chief Financial Officer of InspireMD, IncInspireMD, Inc. announced that Craig Shore, Chief Financial Officer, has decided to retire from the Company after a successor CFO is identified and appointed. Mr. Shore will remain as CFO until his successor is appointed and will assist in a smooth and orderly transition.
Price Target Changed • Dec 11Price target increased by 9.2% to US$4.75Up from US$4.35, the current price target is an average from 2 analysts. New target price is 50% above last closing price of US$3.17. Stock is up 37% over the past year. The company posted a net loss per share of US$0.82 last year.
お知らせ • Dec 10Inspiremd Announces First Patient Enrolled in the Cguardians Ii Pivotal Study of the Cguard Prime Carotid Stent System in Transcarotid Artery Revascularization ProceduresInspireMD, Inc. announced that the first patient has been enrolled in the company’s CGUARDIANS II clinical trial evaluating its CGuard Prime Carotid Stent System in patients undergoing carotid artery stenting via the Transcarotid Artery Revascularization (TCAR) approach. The patient was enrolled by Dr. Patrick Muck at Good Samaritan Hospital, part of the TriHealth System in Cincinnati, Ohio. Dr. Muck serves as both the site principal investigator as well as a co-lead investigator of the CGUARDIANS II study. CGUARDIANS II is a prospective, multi-center, single arm pivotal study that aims to enroll a minimum of 50 evaluable patients. The objective of this study is to evaluate acute device success and technical success of the CGuard Prime when used in conjunction with an FDA-cleared TCAR neuro-protection system in patients at high risk for adverse events from carotid endarterectomy.
お知らせ • Nov 26InspireMD, Inc. Appoints Scott R. Ward to Its Board of DirectorsInspireMD, Inc. announced the appointment of accomplished medical technology executive Scott R. Ward to its Board of Directors. Mr. Ward most recently served as Chief Executive Officer and President of Cardiovascular Systems, Inc. prior to its acquisition by Abbott (NYSE: ABT) in April 2023. Mr. Ward has over 40 years of experience in the healthcare industry, including nearly 30 years at Medtronic, Inc. where he served in various leadership roles including as Senior Vice President and President of the CardioVascular, Neurological and Diabetes businesses. Mr. Ward is the Founder of Raymond Holdings, a firm with activities in venture capital, strategy and transactional advisory services for medical technology and life science companies. He earned his Bachelor of Science in Genetics and Cell Biology, his Master of Science in Toxicology, and his Master of Business Administration, all from the University of Minnesota.
Reported Earnings • Nov 13Third quarter 2024 earnings released: US$0.16 loss per share (vs US$0.15 loss in 3Q 2023)Third quarter 2024 results: US$0.16 loss per share (further deteriorated from US$0.15 loss in 3Q 2023). Revenue: US$1.81m (up 16% from 3Q 2023). Net loss: US$7.89m (loss widened 52% from 3Q 2023). Revenue is forecast to grow 63% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
お知らせ • Nov 04InspireMD, Inc. to Report Q3, 2024 Results on Nov 12, 2024InspireMD, Inc. announced that they will report Q3, 2024 results Pre-Market on Nov 12, 2024
お知らせ • Oct 07InspireMD, Inc. Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent SystemInspireMD, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational Device Exemption (IDE) Application to initiate the CGUARDIANS II pivotal study of its CGuard Prime 80cm Carotid Stent System during transcarotid revascularization (TCAR) procedures. In February 2024, InspireMD announced that Patrick Geraghty, M.D., professor of surgery and radiology, section of vascular surgery at Washington University School of Medicine in St. Louis, MO, and Patrick Muck, M.D., program director and chief of vascular surgery at Good Samaritan Hospital in Cincinnati, OH, have agreed to act as lead investigators for the trial.
お知らせ • Sep 16InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent SystemInspireMD, Inc. announced that it has submitted a Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) seeking marketing approval for the CGuard Prime carotid stent system in the U.S. The PMA application is based on the overwhelmingly positive one-year data from the Company's C-GUARDIANS pivotal clinical trial that were presented at the Leipzig Interventional Course (LINC) 2024 in May. The C-GUARDIANS clinical trial evaluated the safety and efficacy of CGuard for the treatment of carotid artery stenosis. The study enrolled 316 patients across 24 trial sites in the U.S. and Europe. The C-GUARDIANS results showed a primary endpoint1 major adverse event rate of 1.95% through twelve months post-procedure, the lowest such event rate reported for any carotid stent or embolic protection device pivotal trial to date.
Reported Earnings • Aug 06Second quarter 2024 earnings released: US$0.22 loss per share (vs US$0.24 loss in 2Q 2023)Second quarter 2024 results: US$0.22 loss per share. Revenue: US$1.74m (up 5.5% from 2Q 2023). Net loss: US$7.91m (loss widened 56% from 2Q 2023). Revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US.
New Risk • Jul 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 20% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (US$82.9m market cap).
お知らせ • Jul 30InspireMD, Inc. to Report Q2, 2024 Results on Aug 06, 2024InspireMD, Inc. announced that they will report Q2, 2024 results on Aug 06, 2024
Recent Insider Transactions Derivative • Jun 28Independent Director exercised options to buy US$153k worth of stock.On the 24th of June, Michael Berman exercised options to buy 61k shares at a strike price of around US$1.38, costing a total of US$85k. This transaction amounted to 17% of their direct individual holding at the time of the trade. Since September 2023, Michael's direct individual holding has decreased from 318.62k shares to 127.88k. Company insiders have collectively bought US$296k more than they sold, via options and on-market transactions, in the last 12 months.
Reported Earnings • May 15First quarter 2024 earnings released: US$0.20 loss per share (vs US$0.53 loss in 1Q 2023)First quarter 2024 results: US$0.20 loss per share. Revenue: US$1.51m (up 22% from 1Q 2023). Net loss: US$7.03m (loss widened 65% from 1Q 2023). Revenue is forecast to grow 54% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US.
お知らせ • May 09InspireMD, Inc. to Report Q1, 2024 Results on May 14, 2024InspireMD, Inc. announced that they will report Q1, 2024 results Pre-Market on May 14, 2024
Board Change • May 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 2 highly experienced directors. Chair of Scientific Advisory Board Ken Rosenfield was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Apr 20InspireMD, Inc., Annual General Meeting, Jun 10, 2024InspireMD, Inc., Annual General Meeting, Jun 10, 2024, at 10:00 US Eastern Standard Time. Location: 4 Menorat Hamaor St. Tel-Aviv Israel Agenda: To consider the election of two Class 1 directors to serve on board of directors for a term of three years or until his or her successor is elected and qualified, for which Paul Stuka and Gary Roubin are the nominees; to approve the Company's executive compensation; to approve the frequency of future advisory votes on the Company's executive compensation; to consider the ratification of the appointment of Kesselman & Kesselman, Certified Public Accountants, a member of PricewaterhouseCoopers International Limited, as independent registered public accounting firm for the year ending December 31, 2024; and to consider such other business as may properly come before the Annual Meeting.
Major Estimate Revision • Mar 12Consensus revenue estimates decrease by 12%, EPS upgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from US$7.97m to US$7.05m. EPS estimate increased from -US$0.78 to -US$0.76 per share. Medical Equipment industry in the US expected to see average net income growth of 16% next year. Consensus price target of US$4.85 unchanged from last update. Share price fell 6.5% to US$2.46 over the past week.
Reported Earnings • Mar 06Full year 2023 earnings: EPS and revenues exceed analyst expectationsFull year 2023 results: US$0.82 loss per share. Revenue: US$6.21m (up 20% from FY 2022). Net loss: US$19.9m (loss widened 7.7% from FY 2022). Revenue exceeded analyst estimates by 1.8%. Earnings per share (EPS) also surpassed analyst estimates by 5.7%. Revenue is forecast to grow 47% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US.
お知らせ • Feb 29InspireMD, Inc. to Report Q4, 2023 Results on Mar 06, 2024InspireMD, Inc. announced that they will report Q4, 2023 results Pre-Market on Mar 06, 2024
分析記事 • Jan 11Here's Why We're Not Too Worried About InspireMD's (NASDAQ:NSPR) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. By way of example, InspireMD...
Recent Insider Transactions • Dec 05Insider recently bought US$127k worth of stockOn the 30th of November, Gary Roubin bought around 50k shares on-market at roughly US$2.53 per share. This transaction amounted to 13% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Major Estimate Revision • Nov 13Consensus EPS estimates fall by 13%The consensus outlook for fiscal year 2023 has been updated. 2023 expected loss increased from -US$0.77 to -US$0.87 per share. Revenue forecast unchanged at US$6.10m. Medical Equipment industry in the US expected to see average net income growth of 25% next year. Consensus price target of US$4.85 unchanged from last update. Share price fell 6.0% to US$3.14 over the past week.
Price Target Changed • Nov 02Price target increased by 18% to US$4.85Up from US$4.13, the current price target is an average from 2 analysts. New target price is 45% above last closing price of US$3.34. Stock is up 201% over the past year. The company is forecast to post a net loss per share of US$0.77 next year compared to a net loss per share of US$2.35 last year.
お知らせ • Nov 02Inspiremd, Inc. Presents Positive 30-Day Follow-Up Results from the C-Guard®? U.S. Investigational Device Exemption (Ide) Clinical TrialInspireMD, Inc. presented 30-day results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) clinical trial at the Vascular InterVentional Advances (VIVA) meeting, which is being held October 30 through November 2 in Las Vegas, NV. The presentation, which was accepted as a late-breaking abstract, was delivered by Dr. Chris Metzger, System Vascular Chief at OhioHealth in Columbus, OH and principal investigator of the C-GUARDIans trial. The company believe the neuroprotective qualities of C-Guard set it apart from competing stents on the market and should help accelerate the ongoing shift in carotid revascularizations from 'surgery first' to an endovascular 'stent first' approach. InspireMD anticipates reporting primary endpoint results from C-GUARDIANS in the second half of 2024 that may support a Premarket Approval (PMA) application.
お知らせ • Oct 31InspireMD, Inc. to Report Q3, 2023 Results on Nov 06, 2023InspireMD, Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 06, 2023
お知らせ • Oct 05InspireMD, Inc. Announces Management AppointmentsInspireMD, Inc. announced senior leadership additions and changes intended to support the company’s commercial growth initiatives, including potential approval of the CGuard Prime stent platform in the U.S., development of new stent delivery systems, and growth in existing approved territories outside of the U.S. The company announced that it has hired Patrick Verta, MD, as Executive Vice President of Clinical and Medical Affairs. In addition, Shane Gleason, who previously served as InspireMD’s General Manager of North America and VP of Global Marketing, has been promoted to Chief Commercial Officer. Dr. Patrick Verta joins InspireMD from Canary Medical, a developer of implantable remote patient monitoring sensor technology and complementary data and analytics, where he served as Chief Medical Officer. Prior to that, he was Founder and Chief Executive Officer of Axelmed LLC, a consultancy focused on strategy and clinical, scientific, medical, and regulatory affairs for medical device companies. Before Axelmed, he spent the prior five years in various roles at Edwards Lifesciences, most recently as VP of Global Medical Affairs, Clinical Science and Biometrics in the Transcatheter Mitral and Tricuspid Therapies (TMTT) division. Earlier in his career, he held senior leadership positions at Sunshine Heart, Neomend, Abbott Vascular (part of Abbott) and Guidant (acquired by Abbott), among others. Dr. Verta received his Doctor of Medicine (M.D.) from Faculté de Médecine in Paris.
Major Estimate Revision • Aug 14Consensus EPS estimates upgraded to US$0.77 lossThe consensus outlook for fiscal year 2023 has been updated. 2023 losses forecast to reduce from -US$1.37 to -US$0.77 per share. Revenue forecast steady at US$6.07m. Medical Equipment industry in the US expected to see average net income growth of 23% next year. Consensus price target up from US$4.13 to US$4.35. Share price rose 3.5% to US$3.21 over the past week.
Price Target Changed • Aug 09Price target increased by 12% to US$4.35Up from US$3.88, the current price target is an average from 2 analysts. New target price is 40% above last closing price of US$3.10. Stock is up 61% over the past year. The company is forecast to post a net loss per share of US$0.77 next year compared to a net loss per share of US$2.35 last year.
Reported Earnings • Aug 08Second quarter 2023 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2023 results: US$0.24 loss per share. Revenue: US$1.65m (up 7.7% from 2Q 2022). Net loss: US$5.08m (loss widened 9.5% from 2Q 2022). Revenue exceeded analyst estimates by 6.7%. Earnings per share (EPS) also surpassed analyst estimates by 44%. Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US.
お知らせ • Jul 29InspireMD, Inc., Annual General Meeting, Sep 13, 2023InspireMD, Inc., Annual General Meeting, Sep 13, 2023, at 10:00 US Eastern Standard Time. Location: 4 Menorat Hamaor St. Tel-Aviv Israel Agenda: T consider the election of three Class 3 directors to serve on board of directors for a term of three years or until his or her successor is elected and qualified, for which Marvin Slosman, Thomas J. Kester and Kathryn Arnold are the nominees; to approve the potential issuance of shares in the Private Placement Offering; to approve an amendment to Amended and Restated Certificate of Incorporation to limit the liability of certain officers of the Company as permitted by recent amendments to Delaware law; to consider the ratification of the appointment of Kesselman & Kesselman, Certified Public Accountants, a member of PricewaterhouseCoopers International Limited, as independent registered public accounting firm for the year ending December 31, 2023; and to consider such other business as may properly come before the Annual Meeting.
お知らせ • Jul 26InspireMD, Inc. to Report Q2, 2023 Results on Aug 08, 2023InspireMD, Inc. announced that they will report Q2, 2023 results Pre-Market on Aug 08, 2023
お知らせ • Jun 28InspireMD, Inc. Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption Clinical TrialInspireMD, Inc. announced that it completed enrollment of its ongoing C-Guardians U.S. Investigational Device Exemption (IDE) clinical trial, designed to support potential U.S. marketing approval of the CGuard Prime EPS stent system. The C-Guardians clinical trial is evaluating the safety and efficacy of the CGuard™ Carotid Stent System for the treatment of carotid artery stenosis. The study, which commenced enrollment in July 2021, enrolled 315 patients across 25 trial sites in the U.S. and Europe. The trial includes both symptomatic and asymptomatic patients undergoing carotid artery stenting (CAS). The primary endpoint includes the composite of the following: incidence of the following major adverse events: death (all- cause mortality), all stroke, and myocardial infarction (DSMI) through 30-days post-index procedure, based on the Clinical Events Committee (CEC) adjudication or ipsilateral stroke from 31-365-day follow-up, based on CEC adjudication. The performance goal will be considered to have been met if the upper bound of the two-sided 95% confidence interval calculated from the observed primary endpoint rate is <11.6% and the p-value is <0.025. The company anticipates results from the study in second half 2024.
Major Estimate Revision • May 19Consensus estimates of losses per share improve by 46%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from US$5.70m to US$5.90m. EPS estimate increased from -US$2.56 per share to -US$1.37 per share. Medical Equipment industry in the US expected to see average net income growth of 18% next year. Consensus price target down from US$5.15 to US$4.75. Share price rose 23% to US$1.70 over the past week.
お知らせ • May 17InspireMD, Inc. announced that it has received $42.169643 million in funding from Marshall Wace LLP, OrbiMed Advisors LLC, Nantahala Capital Management, LLC, Soleus Capital Management, L.P., Velan Inc. and other investorsOn May 16, 2023, InspireMD, Inc. closed the transaction.
お知らせ • May 06InspireMD, Inc. to Report Q1, 2023 Results on May 15, 2023InspireMD, Inc. announced that they will report Q1, 2023 results on May 15, 2023
Major Estimate Revision • Apr 02Consensus revenue estimates decrease by 37%, EPS upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from US$9.00m to US$5.70m. EPS estimate increased from -US$2.61 to -US$2.56 per share. Medical Equipment industry in the US expected to see average net income growth of 16% next year. Consensus price target down from US$5.60 to US$5.15. Share price rose 3.7% to US$1.13 over the past week.
Price Target Changed • Nov 16Price target decreased to US$5.60Down from US$16.50, the current price target is provided by 1 analyst. New target price is 454% above last closing price of US$1.01. Stock is down 74% over the past year. The company is forecast to post a net loss per share of US$2.59 next year compared to a net loss per share of US$2.03 last year.
Reported Earnings • Nov 10Third quarter 2022 earnings: EPS and revenues exceed analyst expectationsThird quarter 2022 results: US$0.58 loss per share (further deteriorated from US$0.53 loss in 3Q 2021). Revenue: US$1.43m (up 34% from 3Q 2021). Net loss: US$4.53m (loss widened 11% from 3Q 2021). Revenue exceeded analyst estimates by 2.2%. Earnings per share (EPS) also surpassed analyst estimates by 21%. Revenue is forecast to grow 48% p.a. on average during the next 2 years, compared to a 7.4% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 128% per year but the company’s share price has fallen by 60% per year, which means it is significantly lagging earnings.
Recent Insider Transactions • Aug 23Insider recently bought US$68k worth of stockOn the 18th of August, Gary Roubin bought around 36k shares on-market at roughly US$1.91 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$311k more in shares than they have sold in the last 12 months.
Reported Earnings • Aug 10Second quarter 2022 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2022 results: US$0.59 loss per share (down from US$0.46 loss in 2Q 2021). Revenue: US$1.53m (up 48% from 2Q 2021). Net loss: US$4.64m (loss widened 32% from 2Q 2021). Revenue exceeded analyst estimates by 28%. Earnings per share (EPS) also surpassed analyst estimates by 19%. Over the next year, revenue is forecast to grow 37%, compared to a 6.2% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 125% per year but the company’s share price has fallen by 60% per year, which means it is significantly lagging earnings.
Reported Earnings • May 12First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2022 results: US$0.57 loss per share (down from US$0.53 loss in 1Q 2021). Revenue: US$1.18m (up 18% from 1Q 2021). Net loss: US$4.48m (loss widened 38% from 1Q 2021). Revenue missed analyst estimates by 15%. Earnings per share (EPS) exceeded analyst estimates by 29%. Over the next year, revenue is forecast to grow 50%, compared to a 8.8% growth forecast for the industry in the US.
Price Target Changed • Apr 27Price target decreased to US$9.00Down from US$16.50, the current price target is provided by 1 analyst. New target price is 250% above last closing price of US$2.57. Stock is down 61% over the past year. The company is forecast to post a net loss per share of US$3.20 next year compared to a net loss per share of US$2.03 last year.
Reported Earnings • Mar 10Full year 2021 earnings: EPS misses analyst expectationsFull year 2021 results: US$2.03 loss per share (up from US$6.97 loss in FY 2020). Revenue: US$4.50m (up 81% from FY 2020). Net loss: US$14.9m (loss widened 42% from FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 12%. Over the next year, revenue is forecast to grow 31%, compared to a 11% growth forecast for the industry in the US.
分析記事 • Jan 27We Think InspireMD (NASDAQ:NSPR) Needs To Drive Business Growth CarefullyJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Recent Insider Transactions • Jan 01Insider recently bought US$50k worth of stockOn the 28th of December, Gary Roubin bought around 16k shares on-market at roughly US$3.08 per share. In the last 3 months, they made an even bigger purchase worth US$100k. Insiders have collectively bought US$244k more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Nov 19Insider recently bought US$100k worth of stockOn the 17th of November, Gary Roubin bought around 26k shares on-market at roughly US$3.86 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$193k more in shares than they have sold in the last 12 months.
Reported Earnings • Nov 11Third quarter 2021 earnings released: US$0.53 loss per share (vs US$0.96 loss in 3Q 2020)The company reported a soft third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: US$1.07m (up 9.3% from 3Q 2020). Net loss: US$4.07m (loss widened 82% from 3Q 2020).
分析記事 • Oct 05We're Keeping An Eye On InspireMD's (NASDAQ:NSPR) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Sep 20InspireMD: Revolutionizing The Field Of Vascular StentingInspireMD develops and commercializes proprietary stent designs with a proprietary mesh. The Company seeks to change the SoC in the treatment of CAD and other invasive indications utilizing an integrated embolic protection stent platform. The Company’s commercialized products are CE mark approved but not approved for sale in the U.S. The Company has initiated a U.S. registrational IDE clinical trial for CGuard EPS in July 2021.
Recent Insider Transactions • Aug 28Insider recently bought US$93k worth of stockOn the 25th of August, Gary Roubin bought around 22k shares on-market at roughly US$4.19 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Major Estimate Revision • Aug 17Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from US$4.90m to US$4.60m. 2021 losses expected to reduce from -US$547 to -US$2.62 per share. Medical Equipment industry in the US expected to see average net income growth of 20% next year. Consensus price target of US$16.50 unchanged from last update. Share price fell 7.1% to US$3.68 over the past week.
Reported Earnings • Aug 12Second quarter 2021 earnings released: US$0.46 loss per share (vs US$2.93 loss in 2Q 2020)Second quarter 2021 results: Net loss: US$3.51m (loss widened 41% from 2Q 2020).
Reported Earnings • May 12First quarter 2021 earnings released: US$0.53 loss per share (vs US$6.42 loss in 1Q 2020)First quarter 2021 results: Net loss: US$3.24m (loss widened 64% from 1Q 2020).
Reported Earnings • Mar 10Full year 2020 earnings released: US$0.47 loss per share (vs US$4.80 loss in FY 2019)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: US$2.49m (down 33% from FY 2019). Net loss: US$10.5m (loss widened 5.0% from FY 2019). Over the last 3 years on average, earnings per share has increased by 165% per year but the company’s share price has fallen by 82% per year, which means it is significantly lagging earnings.
Analyst Estimate Surprise Post Earnings • Mar 10Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 24%. Earnings per share (EPS) exceeded analyst estimates by 4.5%. Over the next year, revenue is forecast to grow 137%, compared to a 21% growth forecast for the Medical Equipment industry in the US.
分析記事 • Feb 11Trade Alert: Gary Roubin At InspireMD, Inc. (NYSEMKT:NSPR), Has Just Spent US$150k Buying 52% More SharesInvestors who take an interest in InspireMD, Inc. ( NYSEMKT:NSPR ) should definitely note that insider Gary Roubin...